Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Studies

Activation of cannabinoid CB1 receptors induces glucose intolerance in rats
Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls
*Decreased expression of fatty acid amide hydrolase in women with polycystic ovary syndrome
*Effects of cannabinoid antagonist-induced weight loss in polycystic ovarian syndrome (PCOS) patients
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
*Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
The endocannabinoid pathway and the female reproductive organs

For general inquiries:

[email protected]

Questions about your order?

[email protected]

Want to learn more and try Fusion CBD for free?

Let’s grow together #fusionfam

© 2017 - 2020 Fusion Holding Group. All Rights Reserved.

Disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product. The Federal Food, Drug and Cosmetic Act requires this notice.